Tag: Heartflow

New JAMA Network Open Publication Demonstrates the Coronary CT- HeartFlow Analysis Pathway Is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., a leader in revolutionizing precision heartcare, announced that a new cost-effectiveness analysis found a diagnostic pathway which utilizes coronary computed tomography angiography (CTA) with the HeartFlow FFRct Analysis to be “dominant” (less costly and more effective) as compared to stress testing for assessing patients with […]

HeartFlow Appoints Cybersecurity Expert Julie Cullivan to its Board of Directors

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., a leader in revolutionizing precision heartcare, has named Julie Cullivan, Chief Information Officer of Forescout Technologies, Inc., the leader in Enterprise of Things security, to its Board of Directors, effective November 19, 2020. “Julie’s long-time leadership in the technology and cybersecurity industry will provide substantial […]

HeartFlow Applauds Healthcare Stakeholders’ Push for Change in How Coronary Artery Disease is First Diagnosed

Use of coronary CTA instead of stress tests alone results in increased early initiation of preventative therapy and 41% reduction in cardiac death and myocardial infarction1 Publication in the Journal of the American College of Cardiology advocates coronary CTA to detect atherosclerosis and coronary artery blockages versus invasive imaging or […]

New Data Highlight a Significant Increase in Cardiovascular Treatment Efficiency when the HeartFlow Analysis is Incorporated into the Diagnostic Pathway

Nine-month results from FORECAST trial show statistically significant reduction in unnecessary invasive cardiac testing, increase in catheterization lab efficiency, and reduction in repeat non-invasive testing REDWOOD CITY, Calif.–(BUSINESS WIRE)–Late-breaking results presented today confirm that incorporating the HeartFlow® FFRct Analysis into a coronary computed tomography angiogram (CTA)-led diagnostic pathway significantly increases overall […]

HeartFlow Announces FDA Clearance for HeartFlow Planner

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non-invasive, real-time virtual modeling tool for coronary artery disease (CAD) intervention. The HeartFlow Planner will enable interventional cardiologists to virtually model clinical scenarios vessel-by-vessel, explore treatment strategies […]

NHS England to Extend Reimbursement for the HeartFlow Analysis Through Innovation and Technology Payment (ITP) Program

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that NHS England has extended HeartFlow’s participation in the Innovation and Technology Payment (ITP) program for an additional year. As part of the extension, NHS England will provide reimbursement to NHS hospitals for the usage of the HeartFlow FFRct Analysis, a non-invasive cardiac test for stable […]

Use of HeartFlow Planner Leads to Change in Treatment Strategy in Nearly Half of Patients with Coronary Heart Disease

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., today announced new data demonstrating that the use of the investigational HeartFlow Planner, a real-time, non-invasive interactive planning tool, led to a change in treatment strategy in 45% of patients with coronary artery disease (CAD) and reduced the need for invasive physiology. The data from […]

HeartFlow Survey: Fewer than 1/3 of Americans Know Biggest Health Threat

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced the findings of a new consumer survey of more than 1,500 adults across the United States that sheds light on dangerous misconceptions and lack of awareness around heart disease, the leading killer in the U.S. The research shows that while most people are optimistic […]

HeartFlow Initiates PRECISE Randomized Clinical Trial

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced the start of the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial. The first patient was enrolled by Michael C. Turner, M.D., at Imperial Health Cardiovascular Specialists in Lake Charles, LA. The PRECISE trial is designed to compare the usual approach of diagnosing […]